{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:23:07Z","timestamp":1787750587491,"version":"build-2784847793"},"reference-count":57,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Objectives: Fixed-dose combination tablets containing sitagliptin hydrochloride (SG) and metformin hydrochloride (MF) are a mainstay in the clinical management of type 2 diabetes. However, SG is highly susceptible to chemical degradation during storage, particularly in the presence of MF. Herein, a bilayer tablet in which SG and MF are physically separated into distinct layers was designed to enhance the chemical stability of SG while ensuring pharmacokinetic equivalence to the marketed reference product Janumet\u00ae. Methods: The compositions of individual SG and MF compartments were selected based on evaluations of their physical properties and dissolution profiles. Critical process parameters, including the pre- and main compression forces and coating levels of bilayer tablets, were fine-tuned to achieve dissolution characteristics comparable to those of the reference product. Results: Under accelerated storage conditions (40 \u00b0C, 75% relative humidity), the optimized bilayer tablet exhibited superior stability, with total SG-related impurity levels of 0.18% compared with 0.86% in the reference product after six months. Furthermore, in a randomized bioequivalence study in healthy volunteers (n = 30), the SG\/MF bilayer tablet was pharmacokinetically equivalent to the reference product, with all parameters falling within the Food and Drug Administration-mandated regulatory criteria. Conclusions: In conclusion, this SG\/MF bilayer tablet has better storage stability than the reference product and may be an alternative to conventional SG\/MF combination tablets.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091066","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:59:57Z","timestamp":1787749197000},"page":"1066","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Bioequivalent Sitagliptin and Metformin Bilayer Tablet with Improved Chemical Stability"],"prefix":"10.3390","volume":"18","author":[{"given":"In Gyu","family":"Yang","sequence":"first","affiliation":[{"name":"College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Chungnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Young","family":"Han","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Chungnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Young","family":"Jeong","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Chungnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Seo","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Chungnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8878-2972","authenticated-orcid":false,"given":"Myung Joo","family":"Kang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Chungnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Ho","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Wonkwang University, 460 Iksan-daero, Iksan 54538, Jeonbuk, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"B\u00f6hm, A.K., Schneider, U., Aberle, J., and Stargardt, T. (2021). Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0250993"},{"key":"ref_2","first-page":"699","article-title":"Sitagliptin\/metformin (Janumet) as combination therapy in the treatment of type 2 diabetes mellitus","volume":"37","author":"Miller","year":"2012","journal-title":"Pharm. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20142026. Diabetes Care, 49, S183\u2013S215.","DOI":"10.2337\/dc26-S009"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12272-023-01445-2","article-title":"The function, mechanisms, and clinical applications of metformin: Potential drug, unlimited potentials","volume":"46","author":"Liu","year":"2023","journal-title":"Arch. Pharm. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"McCreight","year":"2016","journal-title":"Diabetologia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/bdd.560","article-title":"Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers","volume":"28","author":"Bergman","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_7","first-page":"3546597","article-title":"Formulation and optimization of monolithic fixed-dose combination of metformin HCl and glibenclamide orodispersible tablets","volume":"2020","author":"Belayneh","year":"2020","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/10837450.2020.1772290","article-title":"Development and characterization of metformin hydrochloride- and glyburide-containing orally disintegrating tablets","volume":"25","author":"Gulsun","year":"2020","journal-title":"Pharm. Dev. Technol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jpba.2018.11.023","article-title":"Determination of chemical stability of sitagliptin by LC-UV, LC-MS and FT-IR methods","volume":"164","author":"Gumieniczek","year":"2019","journal-title":"J. Pharm. BioMed Anal."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.xphs.2021.01.011","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Metformin hydrochloride","volume":"110","author":"Metry","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40005-021-00533-z","article-title":"Bilayer tablets with sustained-release metformin and immediate-release sitagliptin: Preparation and in vitro\/in vivo evaluation","volume":"51","author":"Nguyen","year":"2021","journal-title":"J. Pharm. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.17219\/pim\/62511","article-title":"Development of Bilayer Tablets with Modified Release of Selected Incompatible Drugs","volume":"46","author":"Dhiman","year":"2016","journal-title":"Polim. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ijpharm.2013.12.028","article-title":"Review of bilayer tablet technology","volume":"461","author":"Abebe","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"121659","DOI":"10.1016\/j.ijpharm.2022.121659","article-title":"A formulation development strategy for du-al-release bilayer tablets: An integrated approach of quality by design and a placebo layer","volume":"618","author":"Han","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"125944","DOI":"10.1016\/j.ijpharm.2025.125944","article-title":"Structurally tuned drug release from hybrid manufactured tablets via overprinting and overmolding","volume":"682","author":"Xu","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kim, S.H., Han, S.H., Oh, J.S., Seo, D.W., and Kang, M.J. (2024). Evaluation of the ejection pressure for tracking internal cracks during compaction in bilayer tablet formulations using experimental and finite element methods. Pharmaceuticals, 17.","DOI":"10.3390\/ph17030330"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijpharm.2013.05.010","article-title":"Quantitative analysis of the layer separation risk in bilayer tablets using terahertz pulsed imaging","volume":"452","author":"Niwa","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3109\/10837450.2015.1116562","article-title":"Impact of moisture and magnesium stearate functionality on manufacturability of wet granulated metformin tablets","volume":"22","author":"Kestur","year":"2017","journal-title":"Pharm. Dev. Technol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1002\/jssc.201300477","article-title":"Development of a novel RP-HPLC method for the efficient separation of aripiprazole and its nine impurities","volume":"36","author":"Nikolic","year":"2013","journal-title":"J. Sep. Sci."},{"key":"ref_20","unstructured":"United States Pharmacopeial Convention (2024). Sitagliptin Tablets. United States Pharmacopeia and National Formulary (USP\u2013NF), United States Pharmacopeial Convention."},{"key":"ref_21","unstructured":"United States Pharmacopeia (2024). General Chapter <1174> Powder Flow, The United States Pharmacopeial Convention."},{"key":"ref_22","unstructured":"United States Pharmacopeia (2018). General Chapter <1217> Tablet Breaking Force, The United States Pharmacopeial Convention."},{"key":"ref_23","unstructured":"United States Pharmacopeia (2022). General Chapter <1216> Tablet Friability, The United States Pharmacopeial Convention."},{"key":"ref_24","unstructured":"United States Pharmacopeia (2019\/2024). General Chapter <701> Disintegration (Harmonized Text), The United States Pharmacopeial Convention."},{"key":"ref_25","unstructured":"United States Pharmacopeia (2011). General Chapter <711> Dissolution (Harmonized Text), The United States Pharmacopeial Convention."},{"key":"ref_26","unstructured":"International Council for Harmonisation (2003). ICH Q1A(R2): Stability Testing of New Drug Substances and Products, International Council for Harmonisation."},{"key":"ref_27","unstructured":"U.S. Food and Drug Administration (2026). 21 CFR Part 50\u2014Protection of Human Subjects, U.S. Food and Drug Administration."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40005-022-00579-7","article-title":"Strategies for developing Alzheimer\u2019s disease treatments: Application of population pharmacokinetic and pharmacodynamic models","volume":"52","author":"Kang","year":"2022","journal-title":"J. Pharm. Investig."},{"key":"ref_29","unstructured":"U.S. Food and Drug Administration (2014). Bioavailability and Bioequivalence Studies Submitted in NDAs or INDAs\u2014General Considerations, U.S. Food and Drug Administration."},{"key":"ref_30","unstructured":"U.S. Food and Drug Administration (1997). Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.xphs.2021.09.031","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: Sitagliptin phosphate monohydrate","volume":"111","author":"Charoo","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/jps.23852","article-title":"Surfactant-mediated dissolution of metformin hydrochloride tablets: Wetting effects versus ion pairs diffusivity","volume":"103","author":"Desai","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijpharm.2014.06.055","article-title":"Microcrystalline cellulose, a direct compression binder in a quality by design environment\u2014A review","volume":"473","author":"Thoorens","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_34","first-page":"1348","article-title":"The impact of formulation on dissolution coning: Supporting development of a classification system and predictive tool","volume":"8","author":"Brady","year":"2023","journal-title":"Br. J. Pharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1515\/cipms-2016-0015","article-title":"The application of povidone in the preparation of modified release tablets","volume":"29","author":"Kasperek","year":"2016","journal-title":"Curr. Issues Pharm. Med. Sci."},{"key":"ref_36","unstructured":"U.S. Food and Drug Administration (2024). Januvia\u00ae (Sitagliptin) Tablets, Prescribing Information, U.S. Food and Drug Administration."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF03261927","article-title":"Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors","volume":"51","author":"Golightly","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1517\/14656566.2011.580738","article-title":"Sitagliptin: A review","volume":"12","author":"Subbarayan","year":"2011","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rinphs.2015.09.001","article-title":"The importance of binder moisture content in metformin HCl high-dose formulations prepared by moist aqueous granulation (MAG)","volume":"5","author":"Takasaki","year":"2015","journal-title":"Results Pharma Sci."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kim, S.H., Han, S.H., Seo, D.W., and Kang, M.J. (2025). Evaluation of prediction models for the capping and breaking force of tablets using machine learning tools in wet granulation commercial-scale pharmaceutical manufacturing. Pharmaceuticals, 18.","DOI":"10.3390\/ph18010023"},{"key":"ref_41","first-page":"E92","article-title":"Physical mechanical and tablet formation properties of hydroxypropylcellulose: In pure form and in mixtures","volume":"8","year":"2007","journal-title":"AAPS PharmSciTech"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijpharm.2005.10.011","article-title":"Effect of hydroxypropyl cellulose (HPC) on dissolution rate of hydrochlorothiazide tablets","volume":"308","author":"Desai","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"120221","DOI":"10.1016\/j.ijpharm.2021.120221","article-title":"Exploring the performance-controlling tablet disintegration mechanisms for direct compression formulations","volume":"599","author":"Maclean","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/jps.2600790111","article-title":"Effect of the mode of croscarmellose sodium incorporation on tablet dissolution and friability","volume":"79","author":"Gordon","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kim, S.H., Kook, J.H., Seo, D.W., and Kang, M.J. (2023). The effect of compression pressure on the first layer surface roughness and delamination of metformin and evogliptin bilayer and trilayer tablets. Pharmaceuticals, 16.","DOI":"10.3390\/ph16111523"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"120382","DOI":"10.1016\/j.ijpharm.2021.120382","article-title":"Tablet disintegration performance: Effect of compression pressure and storage conditions on surface liquid absorption and swelling kinetics","volume":"601","author":"Markl","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijpharm.2018.01.017","article-title":"Characterisation of pore structures of pharmaceutical tablets: A review","volume":"538","author":"Markl","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jconrel.2024.07.037","article-title":"Impact of immediate release film coating on the disintegration process of tablets","volume":"373","author":"Ma","year":"2024","journal-title":"J. Control Release"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijpharm.2017.03.030","article-title":"Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium","volume":"523","author":"Luo","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.31351\/vol22iss1pp40-49","article-title":"Formulation and evaluation of bilayer tablets containing immediate release aspirin layer and floating clopidogrel layer","volume":"22","author":"Toma","year":"2013","journal-title":"Iraqi J. Pharm. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Jiang, L., Hu, X., and Cai, L. (2022). A drug\u2013drug multicomponent crystal of metformin and dobesilate: Crystal structure analysis and hygroscopicity property. Molecules, 27.","DOI":"10.3390\/molecules27113472"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5155\/eurjchem.4.4.360-365.843","article-title":"Simultaneous determination of sitagliptin and metformin in ternary mixture with sitagliptin acid degradation product","volume":"4","author":"Elkady","year":"2013","journal-title":"Eur. J. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jpba.2018.05.036","article-title":"Degradation caused by incompatibility between sodium stearyl fumarate (PRUV) and AZD7986 in the drug product","volume":"158","author":"Ludvigsson","year":"2018","journal-title":"J. Pharm. BioMed Anal."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2174\/157341212803341681","article-title":"HPLC stability indicating assay method for metformin hydrochloride in bulk drug and tablets and cytotoxicity of degradation products","volume":"8","author":"Stenger","year":"2012","journal-title":"Curr. Pharm. Anal."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.clpt.2005.09.002","article-title":"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses","volume":"78","author":"Herman","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.12793\/tcp.2020.28.e4","article-title":"Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor","volume":"28","author":"Gu","year":"2020","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_57","unstructured":"U.S. Food and Drug Administration, and Center for Drug Evaluation and Research (2001). Statistical Approaches to Establishing Bioequivalence: Guidance for Industry, U.S. Food and Drug Administration."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1066\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:02:34Z","timestamp":1787749354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091066"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091066","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}